Intuitive Surgical, Inc.

Intuitive Surgical, Inc. is the undisputed global leader in robotic-assisted minimally invasive surgery, headquartered in Sunnyvale, California. Founded in 1995, the company has deployed over 10,000 da Vinci surgical systems worldwide and supported more than 17 million procedures, generating US$10.06 billion in 2025 revenue with approximately 17,000 employees across 85+ countries.

Core Business

Intuitive Surgical's core business is the da Vinci surgical ecosystem, comprising multi-port and single-port robotic platforms, a comprehensive portfolio of EndoWrist articulated instruments, integrated stapling and energy devices, and a growing suite of digital solutions. The company operates under a razor-and-blade model where approximately 75% of revenue is recurring — driven by instruments and accessories consumed during each procedure and annual service contracts on installed systems. The second growth engine is the Ion endoluminal system, a robotic bronchoscopy platform for minimally invasive lung biopsy that is rapidly gaining adoption as lung cancer screening programs expand globally. In 2025, da Vinci procedures grew approximately 18% year-over-year, reflecting deepening penetration in general surgery, urology, gynecology, and thoracic applications.

Global Presence

The company's manufacturing operations are anchored in Sunnyvale, California, with additional facilities in Mexico, Germany, and other international locations supporting instrument production, repair, and distribution. With approximately 17,000 employees globally, Intuitive serves customers in 85+ countries. The United States remains the largest market with approximately 65% of revenue, but international markets are growing faster — particularly in Europe, Asia (led by Japan, South Korea, and China), and the Middle East. The company has been expanding its commercial footprint in China despite recent regulatory headwinds from value-based procurement policies.

Key Strengths

Intuitive Surgical possesses the most formidable competitive moat in medical technology, anchored by an installed base exceeding 10,000 systems that would take decades and billions of dollars to replicate. The razor-and-blade business model generates exceptional earnings visibility with 75% recurring revenue. Over 41,000 peer-reviewed publications constitute a clinical evidence moat that new entrants cannot easily match. Procedure growth continues at a 15-18% annual pace, with significant runway in general surgery (only single-digit penetration of addressable procedures) and international markets. The Ion platform represents a second high-growth franchise with limited competition in robotic bronchoscopy.

VerityRank Score

VerityRank Score of 86/100